Tocqueville Asset Management L.P. Purchases New Shares in Viemed Healthcare, Inc. $VMD
Tocqueville Asset Management L.P. recently acquired a new stake of 342,100 shares in Viemed Healthcare, Inc. (NASDAQ:VMD) during the second quarter, valued at approximately $3.9 million. Other institutional investors like BlackRock Inc., Wasatch Advisors LP, and Goldman Sachs Group Inc. also hold significant positions in the company. Viemed Healthcare currently has a "Hold" rating from analysts, with a market capitalization of $326.43 million and a P/E ratio of 23.81.
Viemed Healthcare (VMD) maps 2026 growth after 21% revenue jump
Viemed Healthcare (VMD) reported strong financial results for 2025 with net revenue up 21% year-over-year to $270 million and provided 2026 guidance projecting net revenue between $314 million and $320 million. The company highlights its growing home-based clinical care platform, diversified service lines including ventilation, sleep, and women's health, and a capital-light operating model that supports organic growth, strategic M&A, and shareholder returns. VMD also emphasized its pristine balance sheet with no net debt and significant credit facility availability to fuel future expansion.
VieMed Healthcare posts investor presentation detailing record 2025 results and 2026 guidance
VieMed Healthcare reported record financial results for 2025, with $270.3M in net revenue and $61.4M in Adjusted EBITDA. The company also provided 2026 guidance, projecting net revenue between $314M and $320M, and announced a new share repurchase program. These details were shared in an investor presentation highlighting growth, strong cash generation, and strategic expansion plans.
Viemed Healthcare (VMD) director settles awards, sells 4.2K shares
Viemed Healthcare director Randy E. Dobbs reported the vesting and settlement of 16,763 Restricted Stock Units and 4,191 Phantom Share Units on August 19, 2026. This resulted in the acquisition of common shares and a simultaneous disposition of 4,191 common shares to the company for $8.94 per share. Additionally, Dobbs received a new grant of 16,848 Restricted Stock Units on August 17, 2026, which will vest on its first anniversary.
Viemed Healthcare (NASDAQ: VMD) director granted 12,174 RSUs
Viemed Healthcare director Timothy Smokoff reported several equity compensation events, including the vesting and settlement of previously granted Restricted Stock Units (RSUs) and Phantom Share Units, leading to 3,757 common shares being returned to the company at $8.94 per share. Concurrently, he received new grants of 12,174 RSUs and 3,043 Phantom Share Units, set to vest on their first anniversary. These transactions were not conducted under a Rule 10b5-1 trading plan.
209,066 Shares in Viemed Healthcare, Inc. $VMD Acquired by Rice Hall James & Associates LLC
Rice Hall James & Associates LLC recently acquired 209,066 shares of Viemed Healthcare, Inc. (NASDAQ:VMD) worth approximately $2.38 million, representing 0.55% of the company. Institutional investors now own 74.24% of VMD stock. Viemed Healthcare's latest earnings report showed quarterly revenue in line with estimates but missed EPS expectations, and the stock currently holds an average "Hold" rating from analysts.
GSA Capital Partners LLP Invests $1.46 Million in Viemed Healthcare, Inc. $VMD
GSA Capital Partners LLP recently acquired a new stake of 127,591 shares, valued at approximately $1.46 million, in Viemed Healthcare, Inc. Institutional investors collectively own 74.24% of the company, with several other hedge funds also adjusting their positions. Despite exceeding revenue estimates, Viemed Healthcare missed EPS forecasts, and analyst ratings are predominantly "Hold" with some recent downgrades.
Viemed Healthcare (NASDAQ:VMD) Lowered to "Buy" Rating by Wall Street Zen
Wall Street Zen has downgraded Viemed Healthcare (NASDAQ:VMD) from a "strong buy" to a "buy" rating, with the broader analyst consensus remaining a "hold." This follows Freedom Capital also lowering its rating. The company recently reported quarterly EPS of $0.07, missing the $0.12 consensus, though revenue of $78.1 million slightly exceeded expectations.
(VMD) Risk Channels and Responsive Allocation
This article provides an AI-driven analysis for Viemed Healthcare Inc. (VMD), highlighting weak near and mid-term sentiment but a strong long-term outlook. It outlines three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes risk management and offers real-time signals and multi-timeframe insights for traders.
Viemed (VMD) Q2 2026 Earnings Call Transcript
Viemed Healthcare reported record Q2 2026 revenue of $78.1 million, a 24% year-over-year increase, driven by record ventilator patient counts and growth in sleep therapy and maternal health. The company also announced an all-time high of 12,635 active ventilator patients and significant expansion in other service lines. Despite a dip in adjusted EBITDA margin due to non-recurring gains in the prior year and temporary integration costs, Viemed raised its full-year revenue guidance and lowered its capital expenditure outlook, emphasizing a shift towards less capital-intensive product and service revenue.
Why Viemed Healthcare's (NASDAQ:VMD) Earnings Are Better Than They Seem
Viemed Healthcare's recent earnings, despite seemingly weak stock performance, are better than they appear due to strong cash conversion. The company recorded a negative accrual ratio of -0.11, indicating its free cash flow of US$29m significantly exceeded its statutory profit of US$14.5m. Additionally, unusual items totaling US$2.9m reduced its profit, suggesting that future earnings could improve if these non-recurring expenses do not repeat.
Viemed Healthcare (NASDAQ:VMD) Stock Rating Lowered by Freedom Capital
Freedom Capital downgraded Viemed Healthcare (NASDAQ:VMD) from a "strong buy" to a "hold" rating, while Weiss Ratings simultaneously upgraded it to a "buy." Despite the conflicting ratings, MarketBeat's consensus remains "Hold." The company recently reported Q2 EPS of $0.07, missing analyst estimates, but revenue of $78.1 million slightly exceeded expectations.
Viemed Healthcare | 144: Notice of proposed sale of securities pursuant to Rule 144
This article announces a Form 144 filing by Viemed Healthcare, indicating a proposed sale of securities. The notice is made pursuant to Rule 144 of the Securities Act of 1933, which permits the public resale of restricted and controlled securities if certain conditions are met.
Viemed Healthcare (VMD) Stock Price Sinks As Margin Pressure Clouds Growth
Viemed Healthcare's stock (VMD) dropped almost 16% despite increased Q2 2026 revenue, as net income and profit margins declined year-over-year. The market is reacting to margin pressure, with trailing net profit margin falling to 4.8% from 5.8%, raising questions about whether diversification efforts are effectively boosting profitability. Both bull and bear cases are discussed, highlighting the challenge of turning top-line growth into healthier margins amid cost and mix pressures.
Viemed Healthcare, Inc. $VMD Shares Bought by Arrowstreet Capital Limited Partnership
Arrowstreet Capital Limited Partnership significantly increased its stake in Viemed Healthcare (NASDAQ:VMD) by 101.9% in the first quarter, now owning 1.85% of the company. Other institutional investors like Invesco and Martingale Asset Management also boosted their holdings. Despite beating revenue estimates, Viemed Healthcare missed EPS expectations and analysts currently maintain a "Hold" rating on the stock.
Viemed Healthcare, Inc. (VMD) Stock Price, News, Quote & History
This page provides a comprehensive overview of Viemed Healthcare, Inc. (VMD) stock, including its current price, recent news headlines, and historical performance data. The stock closed at $9.73 on August 7 and has shown positive year-to-date and one-year returns, outperforming the S&P 500 in those periods. Recent news highlights include Q2 2026 earnings call details and estimates, alongside articles discussing insider ownership and growth potential.
Viemed Healthcare Down Over 17%, On Track for Largest Percent Decrease Since January 2019 -- Data Talk
Viemed Healthcare (VMD) stock is experiencing a significant downturn, falling over 17% in intraday trading. This puts the company on track for its largest percentage decrease since January 2019, reflecting a notable negative movement in its share price.
Viemed Healthcare Misses Q2 2026 EPS by 41.7%, Surging Revenue
Viemed Healthcare (NASDAQ:VMD) reported Q2 2026 diluted earnings of $0.07 per share, significantly missing the $0.12 consensus estimate by 41.7%. Despite this, the company saw strong revenue growth, with $78.1 million representing a 23.9% increase year-over-year. The shortfall in earnings, alongside operational expansion serving 12,635 ventilator patients, suggests margin pressures are impacting profitability, though the stock remained largely unchanged.
Earnings call transcript: Viemed Healthcare Q2 2026 profit miss sends shares down 17%
Viemed Healthcare reported mixed Q2 2026 results, with revenue slightly exceeding estimates but earnings falling short, causing a 17% stock drop. The company achieved record revenue of $78.1 million and its highest-ever active ventilator patients, driven by growth across its ventilator, sleep, resupply, and maternal health businesses. Despite strong revenue growth and raised full-year revenue guidance, the profit miss and adjusted EBITDA margin pressure, due to increased operating costs and a shift towards less capital-intensive services, led to investor concern.
Viemed Healthcare Q2 2026 Earnings Call Transcript
Viemed Healthcare reported record Q2 2026 performance with revenue up 24% year-over-year to $78.1 million and a record 12,635 active ventilator patients. The company also saw significant growth in sleep therapy, resupply, and maternal health services, prompting a raised full-year revenue guidance to $314 million-$320 million. Despite a lowered adjusted EBITDA guidance due to investments and growth in lower-margin services, Viemed repurchased shares and maintains a strong financial foundation for continued expansion and productivity gains.
Does Viemed Healthcare Inc (VMD) Justify Its 6.2% Overvaluation
Viemed Healthcare Inc (VMD) reported strong Q2 2026 financial results with net revenues of $78.1 million, a 23.9% increase year-over-year, and significant growth in patient numbers for ventilator and PAP therapy. Despite this growth, net income and Adjusted EBITDA saw declines, and the stock is currently estimated to be 6.2% overvalued according to GuruFocus, with insider selling indicating caution. The company maintains a strong financial position but faces challenges in maintaining profitability amidst rapid expansion.
Viemed Healthcare, Inc. (VMD) Lags Q2 Earnings Estimates
Viemed Healthcare, Inc. (VMD) reported Q2 earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.10. Despite this earnings miss, the company's revenues of $78.1 million surpassed estimates and showed growth from the prior year. The stock has outperformed the S&P 500 year-to-date, and its current Zacks Rank is #3 (Hold), indicating an expected performance in line with the market.
Lazard Asset Management LLC Increases Position in Viemed Healthcare, Inc. $VMD
Lazard Asset Management LLC significantly increased its stake in Viemed Healthcare, Inc. (NASDAQ:VMD) during the first quarter, adding 116,700 shares to own 215,938 shares valued at approximately $1.99 million. Despite this, Viemed Healthcare reported quarterly earnings per share of $0.06, missing the consensus forecast of $0.09, though revenue exceeded estimates at $75.41 million. Analysts currently hold an average "Hold" rating on the stock, while company insiders recently sold a combined 30,000 shares.
Viemed Healthcare (Nasdaq: VMD) lifts Q2 revenue 23.9% on growth
Viemed Healthcare (VMD) reported a 23.9% increase in Q2 2026 revenue, reaching $78.1 million, driven by growth in ventilator rentals, other home medical equipment, and equipment and supply sales, including contributions from the Lehan Drugs acquisition. Despite the revenue growth, net income attributable to Viemed Healthcare, Inc. decreased by 12.4% to $2.76 million, primarily due to higher selling, general, and administrative expenses and a loss on the disposal of property and equipment, partially offset by increased gross profit and lower income tax provision. The company's cash flow from operations remains strong, funding capital expenditures and debt reduction, and it continues to appeal an unresolved Medicare overpayment matter.
Viemed Healthcare Q2 2026 Financial Results | NASDAQ: VMD
Viemed Healthcare, Inc. announced record-setting Q2 2026 financial results, with net revenues of $78.1 million, a 23.9% increase year-over-year. The company also reported an increase in ventilator patients to 12,635 and PAP therapy patients to 37,825. Due to strong performance, Viemed has updated its full-year 2026 net revenue guidance to a range of $314 million to $320 million.
Viemed Healthcare Announces Second Quarter 2026 Financial Results
Viemed Healthcare, Inc. reported record financial results for the second quarter of 2026, with net revenues reaching $78.1 million, a 23.9% increase year-over-year. The company also updated its full-year 2026 guidance, raising the lower end of its net revenue forecast and revising its Adjusted EBITDA and net capital expenditure outlooks due to strong performance and favorable operating trends. Operational highlights include increased ventilator and PAP therapy patient counts and substantial cash flow from operating activities.
(VMD) Movement as an Input in Quant Signal Sets
This article analyzes Viemed Healthcare Inc. (NYSE: VMD) using AI-generated quant signals. It identifies a neutral near and mid-term outlook with a long-term positive bias, noting a mid-channel oscillation pattern. The analysis presents specific trading strategies (Position, Momentum Breakout, Risk Hedging) with entry, target, and stop-loss levels, and provides multi-timeframe signal analysis for different horizons.
Enterprise value to EBIT forward of Viemed Healthcare, Inc. – NASDAQ:VMD
The article focuses on the "Enterprise value to EBIT forward" metric for Viemed Healthcare, Inc. (NASDAQ: VMD). It is a financial data point presented on TradingView, indicating the company's valuation relative to its future earnings before interest and taxes.
VMD Q2'26 Earnings: EPS estimate is 0.12 USD
Viemed Healthcare, Inc. (VMD) is expected to announce its Q2'26 earnings on August 3rd, with an estimated EPS of $0.12 and revenue of $78.00 million. This article provides a comparative table of reported and estimated revenue and EPS figures for recent quarters, highlighting surprises.
Viemed Healthcare Inc (VMD) Financial Health: Profitability & Balance Sheet Analysis
Viemed Healthcare Inc (VMD) currently holds a financial score of 8.51, ranking 14th out of 75 in the Healthcare Providers & Services industry, indicating robust financial health and high operating efficiency. The company's financials, including profitability, balance sheet, and cash flow, contribute to this strong score. However, specific relevant data for Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns have not yet been disclosed by the company.
Viemed Healthcare Inc (VMD) Risk Assessment: Volatility, Financial Risk & Investment Risk
Viemed Healthcare Inc (VMD) has a risk assessment score of 6.28, placing it 29th out of 75 in the Healthcare Providers & Services industry. Its beta of 1.13 suggests higher volatility compared to the S&P 500. The article details various risk metrics including maximum drawdown, volatility, and return-to-drawdown ratios over different periods.
Viemed Healthcare (VMD) Expected to Post Earnings on Monday
Viemed Healthcare (NASDAQ:VMD) is projected to release its Q2 2026 earnings after market close on Monday, August 3rd, with analysts anticipating $0.10 EPS and $78.00 million in revenue. The company's previous quarter missed EPS estimates but exceeded revenue expectations. Insider sales have been noted, while institutional investors hold a significant portion of the stock.
Viemed Healthcare Inc (VMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article discusses Viemed Healthcare Inc (VMD) and its revenue breakdown by business segments and regional revenue, along with profit contribution. However, it explicitly states that the relevant data for these breakdowns have not yet been disclosed by the company. The page provides basic stock information for VMD, including its market capitalization and P/E ratio.
VMD Balance Sheet
This article provides a detailed quarterly and annual balance sheet analysis for Viemed Healthcare Inc (VMD). It allows users to evaluate the company's financial health, examine fundamentals, and calculate key liquidity, leverage, and return on equity ratios. The data includes various assets, liabilities, and shareholders' equity metrics, along with FAQs explaining important financial terms.
Punch & Associates Investment Management Inc. Sells 133,999 Shares of Viemed Healthcare, Inc. $VMD
Punch & Associates Investment Management Inc. reduced its stake in Viemed Healthcare, Inc. by 20% in the first quarter, selling 133,999 shares. Additionally, two company insiders, Director Timothy Smokoff and insider William Frazier, also sold shares of VMD stock. The company recently missed EPS expectations but exceeded revenue estimates, and analysts currently rate the stock as a "Hold."
Viemed Healthcare Inc (VMD) Institutional Confidence
Viemed Healthcare Inc (VMD) has an institutional confidence score of 7.00, placing it 37th out of 75 in the Healthcare Providers & Services industry. Institutional shareholding stands at 72.39%, showing an 8.13% quarter-over-quarter increase. First Eagle Investment is the largest institutional shareholder, holding 493.43K shares.
Forager group discloses 4.9% Viemed Healthcare (VMD) stake in amended 13G
Forager Fund, L.P., Forager Capital Management, LLC, Edward Kissel, and Robert MacArthur have collectively disclosed a 4.9% beneficial ownership stake in Viemed Healthcare, Inc. (VMD) through an amended Schedule 13G filing. This group beneficially owns 1,886,872 shares, representing 4.9% of the 38,336,802 shares outstanding as of April 29, 2026. The filing details the sole and shared voting and dispositive powers within the group, noting that their holdings are below the 5% ownership threshold.
VMD|Viemed Healthcare Inc|Price:11.770|Chg%:+0.100
Viemed Healthcare Inc. (VMD) is trading at $11.77, up 0.86%, with a market cap of $453.54M. The company, an in-home clinical care provider of post-acute respiratory healthcare equipment and services, shows strong fundamentals and high growth potential, though its valuation is considered fairly valued. Analysts currently rate VMD as a "Buy" with a target price of $13.00, indicating an 11.40% upside.
Price to sales forward of Viemed Healthcare, Inc. – NASDAQ:VMD
This article provides a brief mention of the "Price to sales forward" metric for Viemed Healthcare, Inc. (NASDAQ:VMD) within the context of TradingView's financial data offerings. While it lists the company, its stock symbol, and the market it trades on, specific financial figures or analysis are not present. The content primarily highlights TradingView's various features and services.
Liquidity Mapping Around (VMD) Price Events
This article provides an AI-driven analysis of Viemed Healthcare Inc. (VMD), highlighting a near-term neutral sentiment amidst mid and long-term strength. It presents institutional trading strategies for VMD, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis to guide potential investments. The analysis emphasizes compelling upside potential due to the absence of resistance levels above the current price.
Enterprise value to EBIT forward of Viemed Healthcare, Inc. – SWB:VIJ
This article provides financial information for Viemed Healthcare, Inc. (SWB:VIJ) on TradingView, specifically focusing on its enterprise value to EBIT forward. It mentions the company's market status on the Stuttgart Stock Exchange and points to various financial data available on the platform.
Price to sales forward of Viemed Healthcare, Inc. – SWB:VIJ
This article provides financial data for Viemed Healthcare, Inc. (SWB:VIJ), specifically focusing on its forward price-to-sales ratio. It briefly presents the company's financial information, indicating that the market is closed with no trades. The content highlights the availability of various financial and market analysis tools on the TradingView platform where this data is presented.
Price to earnings forward of Viemed Healthcare, Inc. – SWB:VIJ
The article displays the "Price to earnings forward" metric for Viemed Healthcare, Inc. (SWB: VIJ) on the Stuttgart Stock Exchange. It indicates that the market was closed and no trades occurred, providing a snapshot of the company's financial data on TradingView. The content is primarily a data placeholder within a financial platform's interface.
Viemed Healthcare schedules Q2 2026 earnings conference call
Viemed Healthcare, Inc., a national provider of home-based healthcare solutions, has scheduled its Second Quarter 2026 Earnings Conference Call for August 4, 2026, at 11:00 a.m. EDT. The company will discuss its financial performance and operational results. Access details for the live broadcast and a post-event replay on its Investor Relations website have been provided.
Viemed Healthcare schedules Q2 2026 earnings call
Viemed Healthcare Inc. has scheduled its second-quarter 2026 earnings conference call for August 4, 2026, at 11:00 a.m. EDT. A live audio webcast of the call will be available online. This news brief was generated by Public Technologies (PUBT) using AI, based on original content from Viemed Healthcare Inc.
Viemed Sets Aug. 4 Earnings Call on Home-Based Healthcare
Viemed Healthcare (NASDAQ: VMD) has announced its Second Quarter 2026 earnings conference call for Tuesday, August 4, 2026, at 11:00 a.m. EDT. Investors can join by phone or via a live audio webcast, with a replay available afterward on the company's investor relations website. Viemed specializes in providing home medical equipment and post-acute healthcare services, focusing on respiratory, chronic care, and women's health through technology-enabled clinical support.
Viemed Healthcare Announces Second Quarter 2026 Earnings Conference Call Details
Viemed Healthcare, Inc. will host its Second Quarter 2026 Earnings Conference Call on Tuesday, August 4, 2026, at 11:00 a.m. EDT. Interested parties can participate via phone or live audio webcast. A replay will be available on the company's investor relations website.
Enterprise value to EBITDA forward of Viemed Healthcare, Inc. – FWB:VIJ
The article focuses on the enterprise value to EBITDA forward for Viemed Healthcare, Inc. (FWB:VIJ). It appears to be a financial data page from TradingView, providing an overview of the company's financial metrics. The page highlights the enterprise value to EBITDA forward and provides various links related to markets, products, community, and brokerage services.
Form S-1/A Viemed Healthcare Inc For: 13 July By Investing.com
This article announces the filing of Form S-1/A by Viemed Healthcare Inc. on July 13. It is a brief, procedural news item indicating a regulatory filing by the company, with no further details provided in the main content.
Form S-1/A Viemed Healthcare Inc For: 13 July By Investing.com
This article announces the filing of Form S-1/A by Viemed Healthcare Inc. for July 13. It is a brief financial market announcement from Investing.com, typical of regulatory filings. The content primarily lists market data and unrelated news, offering no further details on the S-1/A filing itself.
